InvestSMART

PainChek Ltd (ASX: PCK) - Announcements

- Current share price for PCK : $0.099

ASX company news and announcements for PainChek Ltd (PCK) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All PainChek Ltd (PCK) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than PainChek Ltd (PCK), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for PainChek Ltd (PCK)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$21 Proposed issue of securities - PCK 28 Jul 2025 9:58AM $0.040 $0.099 risen by 147.50%
$21 Investor Presentation 28 Jul 2025 9:58AM $0.040 $0.099 risen by 147.50%
$21 Strongly Supported A$7.5m Placement to Drive Int. Growth 28 Jul 2025 9:58AM $0.040 $0.099 risen by 147.50%
$21 Trading Halt 24 Jul 2025 9:20AM $0.040 $0.099 risen by 147.50%
$21 Final US FDA De Novo Clearance Submission Completed 21 Jul 2025 9:01AM $0.039 $0.099 risen by 153.85%
$21 Notification of cessation of securities - PCK 11 Jul 2025 1:40PM $0.041 $0.099 risen by 141.46%
$21 Change in Directors' Interest Notice x 5 7 Jul 2025 11:47AM $0.039 $0.099 risen by 153.85%
$21 Notification regarding unquoted securities - PCK 7 Jul 2025 11:27AM $0.039 $0.099 risen by 153.85%
$21 PainChek Reports Strong Quarterly Sales Growth 3 Jul 2025 9:01AM $0.044 $0.099 risen by 125%
$21 Application for quotation of securities - PCK 6 Jun 2025 4:01PM $0.040 $0.099 risen by 147.50%
$21 PainChek has productive final FDA De Novo clearance meeting 5 Jun 2025 8:33AM $0.055 $0.099 risen by 80%
$21 PainChek partners with Eldermark to expand US market reach 27 May 2025 8:50AM $0.048 $0.099 risen by 106.25%
$21 PainChek appoints head of Business Development for US market 20 May 2025 9:17AM $0.044 $0.099 risen by 125%
$21 Notification regarding unquoted securities - PCK 19 May 2025 3:26PM $0.044 $0.099 risen by 125%
$21 Notification of cessation of securities - PCK 19 May 2025 3:15PM $0.044 $0.099 risen by 125%
$21 Quarterly Investor Presentation April 2025 1 May 2025 8:49AM $0.035 $0.099 risen by 182.86%
$21 Quarterly Activities/Appendix 4C Cash Flow Report 30 Apr 2025 8:47AM $0.039 $0.099 risen by 157.14%
$21 Quarterly update and Appendix 4C webinar 29 Apr 2025 1:41PM $0.036 $0.099 risen by 175%
$21 R&D Tax Refund, FDA Review of Adult App & Infant App Launch 16 Apr 2025 8:44AM $0.035 $0.099 risen by 182.86%
$21 Notification regarding unquoted securities - PCK 27 Mar 2025 11:01AM $0.034 $0.099 risen by 191.18%
$21 Notification regarding unquoted securities - PCK 27 Mar 2025 10:55AM $0.034 $0.099 risen by 191.18%
$21 Application for quotation of securities - PCK 27 Mar 2025 10:50AM $0.034 $0.099 risen by 191.18%
$21 Update to previous announcement 17 Mar 2025 12:42PM $0.029 $0.099 risen by 241.38%
$21 PainChek to present at NWR Virtual Healthcare Conference 17 Mar 2025 9:30AM $0.029 $0.099 risen by 241.38%
$21 Notification regarding unquoted securities - PCK 6 Mar 2025 9:55AM $0.030 $0.099 risen by 230%

76 - 100 of 470 results

Page 4 of 19

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.